uniQure. Every tracked FinTwit mention of $QURE, newest first. 54 mentions since the first on Sep 19, 2025. See the price chart.
April 2026 · 3 mentions
Apr 30
Adam Feuerstein ✡️ — $QURE
-- Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026
-- Type B Meeting with U.S. FDA granted in second quarter; exp…↗
Serenity — Serenity's Followers Favorite Stock Parabolic Growth ETF:
The most anticipated ETF of all time:
$TRT - $5.88
$HGRAF - $4.49
$SIVE - 9.9 SEK
$QURE - $17.21
$AEHR - $45.08
$ENVX -…↗
March 2026 · 17 mentions
Mar 19
Adam Feuerstein ✡️ — This week's Biotech Scorecard newsletter:
Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era
$REPL Pierre Fabre $ATRA $QURE $CAPR $RGNX
https://t.co…↗
Mar 19
Adam Feuerstein ✡️ — Let's look at how the FDA is treating $SRPT and $QURE differently.
The FDA grants accelerated approval to Amondys and Vyondys to treat Duchenne muscular dystrophy. Sarepta conduc…↗
Mar 8
Adam Feuerstein ✡️ — Too funny. @emilyakopp (below) outs Vinay Prasad as the host of Thursday’s HHS/FDA media call to discuss $QURE.↗
Adam Feuerstein ✡️ — (Hopefully) Final word today on the Makary $QURE (or was it $RGNX) thing:
Bottom line: Makary shouldn't be talking publicly about unresolved drug applications. Uniqure doesn't ev…↗
Feb 26
Adam Feuerstein ✡️ — @BiotechAnalysst $RGNX therapy is delivered intrathecally into the spine, not via a burr hole in the head like $QURE↗
Feb 26
Adam Feuerstein ✡️ — $QURE down this morning on comments made by FDA Commissioner Marty Makary to CNBC's Becky Quick.
In a discussion about rare-disease drug approvals and Vinay Prasad, Makary said t…↗
Adam Feuerstein ✡️ — On this week's Readout LOUD podcast: We chatted withLauren Holder @laurencurehd about $QURE AMT-130 and the FDA. Lauren is a Huntington's disease patient advocate and is, herself,…↗
Jan 9
Adam Feuerstein ✡️ — $QURE said FDA meeting scheduled to discuss AMT-130. No timing provided.↗
December 2025 · 1 mention
Dec 4
Adam Feuerstein ✡️ — $QURE FDA update:
In the final meeting minutes, and consistent with uniQure’s November 3, 2025 press release, the FDA conveyed that data submitted from the Phase I/II studies of…↗
November 2025 · 16 mentions
Nov 13
Adam Feuerstein ✡️ — In this week's Biotech Scorecard:
-- $QURE CEO Matt Kapusta dined privately with investors on Tuesday night -- and said some stuff, according to two attendees who filled me in.
-…↗
Nov 13
Adam Feuerstein ✡️ — The FDA’s Vinay Prasad wrote today’s “plausible mechanism” paper offering a regulatory roadmap for personalized therapies.
Prasad is also refusing to allow $QURE to seek approval…↗
Nov 10
Adam Feuerstein ✡️ — $QURE Q&A largely uneventful
Mgmt confirmed FDA guidance from Nov. 2024 meeting was study data+ECA supported a BLA filing.
Doesn't expect new mtg meetings to change FDA shift, b…↗
Adam Feuerstein ✡️ — @A_May_MD @BlaseBio I would say Cathie Wood staying out of $QURE would be a bullish sign.↗
September 2025 · 9 mentions
Sep 25
Adam Feuerstein ✡️ — @avidresearch I don't know anything about the $BHVN external control or how it was constructed, so I can't comment. $QURE is sourcing its ECA from a very large, independent and wel…↗
Sep 25
Adam Feuerstein ✡️ — Uniqure $QURE and its Huntington’s therapy win the week in biotech. Plus: Why Stoke Therapeutics’ $STOK quiet move higher makes sense
https://t.co/C3VnHKtTX2↗
Sep 25
Adam Feuerstein ✡️ — This week's Biotech scorecard newsletter: (Almost) 100% positive vibes
1. $QURE, of course.
The 75% slowing of disease progression reported by Uniqure with its Huntington’s dis…↗
Adam Feuerstein ✡️ — Hint: You might learn something more about the "senior FDA official" in this $QURE piece.
https://t.co/ceDE0TXjdI↗
Mar 6
Adam Feuerstein ✡️ — New from me on $QURE and FDA. Free, no paywall.
The FDA, urged to avoid controversy, creates a new headache with attack against UniQure
Anonymous diatribe from a senior official…↗
Mar 6
Adam Feuerstein ✡️ — Some context for the UniQure $QURE post below:
Earlier today, the FDA held a media call with the same "senior FDA official" who spoke to me (and other reporters) individually earl…↗
Mar 5
Adam Feuerstein ✡️ — @anish_koka The UniQure $QURE CEO is on the record, the "senior FDA official" is not. The interview with the "senior FDA official" was facilitated through official HHS/FDA channels…↗
Mar 5
Adam Feuerstein ✡️ — Plus... Deeper cuts from my reporting this week. You asked some very thoughtful questions about the $QURE FDA situation. I responded...
Including: What is "sham surgery" in the…↗
Mar 5
Adam Feuerstein ✡️ — In this week's Biotech Scorecard newsletter: The extremism of the FDA’s Peter Marks and Vinay Prasad has come with costs
Two regulators, two extreme regulatory philosophies, one r…↗
Mar 3
Adam Feuerstein ✡️ — Read more on $QURE and FDA from me here:
FDA is ‘not convinced’ UniQure’s Huntington’s therapy has benefit, senior official says
Company accuses agency of reversal but hopes to s…↗
Mar 3
Adam Feuerstein ✡️ — New reporting from me taking you inside the $QURE - FDA Huntington's gene therapy imbroglio.
I spoke to a senior FDA official late yesterday, who told me agency reviewers "are no…↗
Mar 2
Adam Feuerstein ✡️ — $QURE UniQure plans to seek approval for Huntington’s therapy still blocked by FDA
https://t.co/jqzDB5bTWS↗
Mar 2
KaizenInvestor — $QURE drops 45% after earnings.
That painful 45% drop makes sense given the severe regulatory roadblocks just announced. The biggest blow is the FDA rejecting early approval for…↗
Mar 2
Adam Feuerstein ✡️ — $QURE AMT-130 update: Still blocked
The FDA stated that it cannot agree that data from the Phase I/II studies, compared to an external control, are sufficient to provide the prim…↗
Mar 2
KaizenInvestor — $QURE surged 375% last September after releasing highly anticipated topline data for AMT-130, its lead gene therapy candidate for Huntington's disease. The phase I/II study results…↗
Mar 1
KaizenInvestor — Some interesting earnings next week, I’ll be looking at following earnings.
Monday: $BRK.B, $QURE, $RIOT, $BBAI, $MDB, $PLUG, $QUBT, $ASTS, $ACHR
Tuesday: $SE, $ASM.AS, $CRWD, $…↗
Adam Feuerstein ✡️ — This week's Biotech Scorecard newsletter: The old Vinay Prasad never left. He just changed jobs
Submissions to the FDA are handled by teams of reviewers, of course. But when I lo…↗
— $QURE call -- opening remarks from CEO Matt Kapusta:
The FDA's shift on AMT-130 data was "surprising, " "disappointing" and a "notable shift" from multiple meetings over the past…
Adam Feuerstein ✡️ — $QURE - nothing new in this morning's earnings release re: AMT-130 and the FDA situation. Conference call at 8:30 am ET.↗
Nov 6
Adam Feuerstein ✡️ — @Ssunten_ I don't know you, but based on your X timeline, you are extremely devoted to $QURE. I'm sure the company appreciates your support. Good luck.↗
Nov 6
Adam Feuerstein ✡️ — @Ssunten_ I appreciate you reading the article. It was a fair and balanced take on the current $QURE situation, based on what we know now. The assumption that this is entirely the…↗
Nov 6
Adam Feuerstein ✡️ — This week's Biotech Scorecard newsletter: The FDA is a mess, but don't blame it for everything
I write about $QURE and $BHVN
Re: Uniqure and its gene therapy for Huntington's di…↗
Nov 5
Adam Feuerstein ✡️ — $BHVN approval was a coin flip at best, so the CRL and the reasons for it are not really a surprise. $QURE is different in some ways.
This is what I wrote on Oct. 9
We should le…↗
Nov 5
Adam Feuerstein ✡️ — $QURE $BHVN The question I (we) now struggle to understand:
Is the "new" FDA now uniformly opposed to using external /historical controls in drug applications?
Or
Were there si…↗
Nov 3
Adam Feuerstein ✡️ — @basadomente I'd like to speak to $QURE simply because I prefer to hear from them directly, and not filtered through analyst notes. Not asking for preferential treatment, simply th…↗
Nov 3
Adam Feuerstein ✡️ — $QURE has been talking to analysts and investors all day. The company declined to speak to me.
Here's what mgmt is apparently saying about the FDA, per Cantor's Kristen Kluska ht…↗
Nov 3
Adam Feuerstein ✡️ — @Biohazard3737 $QURE You may have already mentioned this theory, but at the risk of repeating, I wonder if today's FDA guidance (or pulling the old) is an effort to be more helpfu…↗
Nov 3
Adam Feuerstein ✡️ — Uniqure’s $QURE FDA submission for its Huntington’s disease therapy thrown into question https://t.co/tfZxYM9iKL via @DrewQJoseph
12 hours of head-spinning FDA news....↗
Nov 3
Adam Feuerstein ✡️ — On $QURE: I wrote this in my Sept. 25 newsletter:
"Bear in mind: What we have seen so far of the AMT-130 data are mentioned in a Uniqure press release. Fairly detailed, yes, but…↗
— These microcap companies have active discussions on our forum in the last 24 hours.
$SNWV $CYBT.CN $RNGE $MDP.TO $DSW.L $QURE $CLPT $SMLR $AUUA.V $VOXR $INT.ST $URL.CN $REACH.OL $…
Adam Feuerstein ✡️ — $CLPT higher on $QURE results. ClearPoint sells the imaging equipment that allows the precise surgical implantation of the gene therapy into the brain.↗
Sep 24
Adam Feuerstein ✡️ — $QURE Also AMT-130 showed stat sig 60% disease slowing on TFC, assesses patients’ ability to work, drive and perform other functions of daily life. NfL also lower.
Gene therapy i…↗
Sep 24
Adam Feuerstein ✡️ — BREAKING: $QURE experimental gene therapy for Huntington’s slowed disease progression by 75% after three years, study shows.
Very strong results. FDA filing in Q1 '26. My story li…↗
Sep 19
Adam Feuerstein ✡️ — Happy Friday evening.
$MLTX and $QURE readouts still pending as we roll towards the end of September.↗